Noah M. Hahn, M.D.

Associate Professor of Medicine
Department of Oncology and Urology

Johns Hopkins University School of Medicine
The Koch Cancer Research Building 1550 Orleans Street, Room 1M51 Baltimore, MD 21287

Office: 443-287-2886


Fax: 410-614-8397

Noah M. Hahn, MD was born in Valparaiso, Indiana and attended the University of Notre Dame where he graduated in 1994 with a degree in mechanical engineering.  He finished his medical school training at the Indiana University School of Medicine in 2000.  He completed a transitional year internship at Emory University in 2001, his internal medicine residency at Duke University in 2003, and his hematology and oncology fellowship at the Indiana University Simon Cancer Center (IUSCC) in 2006.  Upon completion of his fellowship training, he was appointed to the IUSCC oncology faculty and served as the leader of their prostate and bladder cancer programs.  In addition, he served as the chief scientific officer of the Hoosier Cancer Research Group (formerly the Hoosier Oncology Group) and the executive officer of the Big Ten Cancer Research Consortium.  In April 2014, Dr. Hahn joined the Johns Hopkins University School of Medicine faculty as the director of the medical oncology bladder cancer program with the academic rank of associate professor of oncology and urology.  

Dr. Hahn is an internationally recognized authority in the conduct of bladder cancer novel therapeutic clinical trials and translational investigations.  He maintains an active clinical practice and sees patients with urothelial cancers of all locations and stages including non-muscle invasive bladder cancer.  He is one of the few oncologists in the world leading a clinical trial in non-muscle invasive bladder cancer.  In addition, Dr. Hahn continues to care for patients with non-urothelial genitourinary malignancies including prostate, testicular, and other rare tumors.  Dr. Hahn's clinical and translational research interests focus on improving outcomes for patients with urothelial cancers through:

  1. The identification and validation of predictive biomarkers relevant to urothelial cancers, and
  2. The identification of novel therapeutic and preventative targets for urothelial cancer patients.   

In addition to his efforts at Johns Hopkins, Dr. Hahn serves as the bladder cancer chairman of the Eastern Cooperative Oncology Group (ECOG), co-chairs the Hoosier Cancer Research Network genitourinary oncology clinical trials working group, participates on the NCI Bladder Cancer Task Force, and serves on the scientific advisory board of the Bladder Cancer Advocacy Network. 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287

urology second opinion urology second opinion